Keywords Bretylium Trade Name: generic Drug Class: Antiarrhythmic Mechanism of Action: (after an initial phase of causing the release of catecholamines) Interferes with the neuronal release of catecholamines Bretylium also lengthens the duration and effective refractory period in heart tissue (a Class III effect), an effect that is most pronounced in ischemic cells (which have shortened action potential durations) Indications: No longer available in the United States Previously used for attempted resuscitation from ventricular fibrillation after lidocaine and cardioversion have failed Side Effects: Precipitation of cardiac arrhythmias at the onset of drug therapy due to its ability to cause the initial release of catecholamines (when used as an antiarrhythmic)
Lower OGN expression, frequently observed in both PCOS and OC tissues, was associated with altered hormone signaling and poor prognosis, potentially promoting tumor progression through dysregulation of FSHR and m6A methylation
Immunohistochemical images were taken on a multispectral scanning microscope imaging system (TissueGnostics, Austria), and the average optical density (MOD) was calculated by the software Image Pro-plus
Your provider may reference these predispositions when documenting medical necessity, and it may support exploration of compounded alternatives if branded coverage remains limited
Hormonal Treatments Oral contraceptives
